iQure Pharma Welcomes Prof. Iris Loew-Friedrich as New Clinical and R&D Advisor

iQure Pharma Welcomes New Clinical and R&D Advisor

Princeton, N.J., July 2, 2025 – iQure Pharma, a clinical-stage biotechnology firm, has announced the hiring of Prof. Dr. Iris Loew-Friedrich as its newest Clinical and R&D Advisor. Prof. Loew-Friedrich brings over three decades of robust experience in clinical development and regulatory strategy, crucial for steering iQure's innovative research in central nervous system (CNS) disorders.

Iris Loew-Friedrich previously held a prestigious role at UCB, where she was the Executive Vice President and Chief Medical Officer. Her impressive career spanned from 2008 to 2024, leading global clinical programs across CNS, immunology, and rare diseases. Notably, she played a pivotal role in securing various drug approvals, including those for bimekizumab (Bimzelx®) and rozanolixizumab (Rystiggo®). Under her stewardship, UCB achieved significant regulatory successes in the United States and European markets.

Before UCB's acquisition of Schwarz Pharma in 2007, she pioneered the integrated global development organization at Schwarz, successfully advancing strategic partnerships and new therapies such as lacosamide (Vimpat®). Her early career experiences at renowned companies like BASF Pharma and Aventis saw her contribute to major drug developments, including the well-known adalimumab (Humira®).

Prof. Loew-Friedrich, who holds an MD and has been certified in internal medicine, also possesses a PhD in cell biology. She began her journey in the medical field as a physician-scientist and associate professor in Frankfurt, where her insights into cellular processes initiated her passion for drug development.

During her introduction to the iQure team, CEO Pawel Zolnierczyk expressed enthusiasm regarding her appointment, stating, "Iris’s comprehensive expertise in clinical development significantly strengthens iQure’s capabilities in advancing our developmental strategies. Her insights and experiences will guide us effectively as we strive for growth and innovation in CNS therapies."

iQure Pharma specializes in addressing CNS disorders by restoring glutamate balance—a critical factor in preventing neuronal damage associated with excitotoxicity. Their leading compound, iQ-007, is a groundbreaking oral medication in Phase 1 clinical trials, focused on treating treatment-resistant epilepsy. Prof. Loew-Friedrich’s extensive background will likely aid in shaping the next phases of development not just for iQ-007 but also for forthcoming therapies targeting neurodegeneration and chronic pain conditions.

With her valuable contributions, iQure is well-positioned to make significant advancements in CNS disorder treatments, continuing their commitment to innovative solutions that could transform patient outcomes.

For further information about iQure Pharma and its initiatives, visit iQure Pharma's official website.